International Journal of Molecular Sciences Article Discovery of Novel Non-Steroidal Cytochrome P450 17A1 Inhibitors as Potential Prostate Cancer Agents Tomasz M. Wróbel 1,2,* , Oksana Rogova 1, Kasper L. Andersen 3 , Rahul Yadav 4, Simone Brixius-Anderko 4, Emily E. Scott 4,5, Lars Olsen 1,6, Flemming Steen Jørgensen 1 and Fredrik Björkling 1 1 Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark;
[email protected] (O.R.);
[email protected] (L.O.);
[email protected] (F.S.J.);
[email protected] (F.B.) 2 Department of Synthesis and Chemical Technology of Pharmaceutical Substances, Medical University of Lublin, Chod´zki4a, 20093 Lublin, Poland 3 Biotech Research and Innovation Centre (BRIC), University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen, Denmark;
[email protected] 4 Department of Medicinal Chemistry, University of Michigan, 428 Church Street, Ann Arbor, MI 48109-1065, USA;
[email protected] (R.Y.);
[email protected] (S.B.-A.);
[email protected] (E.E.S.) 5 Department of Pharmacology, University of Michigan, 428 Church Street, Ann Arbor, MI 48109-1065, USA 6 Protein Engineering, Novozymes A/S, Krogshøjvej 36, DK-2880 Bagsvaerd, Denmark * Correspondence:
[email protected]; Tel.: +48-814-487-273 Received: 1 June 2020; Accepted: 7 July 2020; Published: 9 July 2020 Abstract: The current study presents the design, synthesis, and evaluation of novel cytochrome P450 17A1 (CYP17A1) ligands. CYP17A1 is a key enzyme in the steroidogenic pathway that produces androgens among other steroids, and it is implicated in prostate cancer.